Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.46 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.47 |
| ▸ | FABP7 | O15540 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1436990 | 0.98 | KMT2A (0.56) | KMT2AFABP5FABP7CA1CA2 | |
| Bromide SCHEMBL15671138 | 0.97 | KMT2A (0.55) | KMT2AFABP5FABP7CA1CA2 | |
| Trifluoroacetic Acid SCHEMBL5553261 | 0.89 | KMT2A (0.48) | KMT2AFABP5FABP7CA1CA2 | |
| Hydrochloric Acid SCHEMBL6366019 | 0.88 | KMT2A (0.52) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL1901193 | 0.87 | KMT2A (0.53) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL8453691 | 0.86 | KMT2A (0.52) | KMT2AFABP5FABP7CA1CA2 | |
| Hydrochloric Acid SCHEMBL4163755 | 0.86 | KMT2A (0.50) | KMT2AFABP5FABP7CA1CA2 | |
| Bromide SCHEMBL16269651 | 0.85 | KMT2A (0.52) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL5350781 | 0.85 | KMT2A (0.51) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL7121595 | 0.85 | KMT2A (0.51) | KMT2AFABP5FABP7CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4590341-A1 | POLYMERS WITH DUAL THERAPEUTIC AGENTS | Sony Group Corporation (JP) | 2025-07-30 | — | — | EP | disclosed |
| CN-120152742-A | Polymer with dual therapeutic agents | 索尼集团公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-119490505-A | Folic acid compound-containing composition and near infrared fluorescence capturing system | 新斗生物科技(苏州)有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-119490506-A | Small molecule compound targeting folic acid receptor and preparation method, composition and application thereof | 新斗生物科技(苏州)有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-117679529-B | Aptamer-multivalent drug conjugate as well as preparation method and application thereof | 成都中医药大学 | 2024-05-03 | — | — | CN | disclosed |
| EP-4346906-A1 | ANTHRACYCLINE ANTIBODY CONJUGATES | Seagen Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024062319-A1 | POLYMERS WITH DUAL THERAPEUTIC AGENTS | Sony Group Corporation (JP) | 2024-03-28 | — | — | WO | disclosed |
| CN-117679529-A | Aptamer-multivalent drug conjugate as well as preparation method and application thereof | 成都中医药大学 | 2024-03-12 | — | — | CN | disclosed |
| EP-3287458-B1 | HYBRID CYCLIC LIBRARIES AND SCREENING THEREOF | UNIV JOHNS HOPKINS (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20220127605-A1 | NUCLEIC ACID CONJUGATE | KYOWA KIRIN CO., LTD. (JP) | 2022-04-28 | — | — | US | disclosed |
| US-7972827-B2 | Photoswitchable method for the ordered attachment of proteins to surfaces | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100292104-A1 | Photoswitchable Method for the Ordered Attachment of Proteins to Surfaces | U.S. DEPARTMENT OF ENERGY | 2010-11-18 | — | — | US | disclosed |
| WO-2010046900-A2 | RGD-CONTAINING PEPTIDOMIMETICS AND USES THEREOF | STEBA BIOTECH N.V. (NL) | 2010-04-29 | — | — | WO | disclosed |
| US-7700334-B2 | Photoswitchable method for the ordered attachment of proteins to surfaces | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2010-04-20 | — | — | US | disclosed |
| US-7556863-B2 | encapsulated magnetic nanoparticle central core of samarium-cobalt (SmCo5); endcapped with thiol-bound functional group-containing spacer groups; cancer-binding agent for magnetic resonance imaging; tissue-targeted therapy for detecting or treating cancer | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2009-07-07 | — | — | US | disclosed |
| US-20080305337-A1 | encapsulated magnetic nanoparticle central core of samarium-cobalt (SmCo5); endcapped with thiol-bound functional group-containing spacer groups; cancer-binding agent for magnetic resonance imaging; tissue-targeted therapy for detecting or treating cancer | BERNING DOUGLAS E | 2008-12-11 | — | — | US | disclosed |
| US-20070225482-A1 | Photoswitchable Method for the Ordered Attachment of Proteins to Surfaces | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC | 2007-09-27 | — | — | US | disclosed |
| US-7226636-B2 | Suspension of magnetic particles in liquid; adding a gold compound; mixing with reducing agents | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2007-06-05 | — | — | US | disclosed |
| US-20050095651-A1 | Photoswitchable method for the ordered attachment of proteins to surfaces | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-05-05 | — | — | US | disclosed |
| US-20050025969-A1 | Suspension of magnetic particles in liquid; adding a gold compound; mixing with reducing agents | LOS ALAMOS NATIONAL SECURITY, LLC | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127605-A1 | NUCLEIC ACID CONJUGATE | NSUN3, NSUN2, RNASEH1 | CA2 1977/4885HTR2A 4666/4885KMT2A 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.